Merck shares what it has in store for this year

Merck recently shared what it is working on for the 2010 year and beyond in terms of the drugs they are developing.

They're looking at five new drugs to enter the market this year:

1. Boceprevir,for hepatitis C
2. Janumet XR (sitagliptin/metformin) and NOMAC/E2 (all USA), which is a new diabetes combo
3. MK-0431D, for sitagliptin and simvastatin
4. Ridaforolimus, a sarcoma drug (worldwide)
5. Daptomycin, injectable antibiotic

Noting the new possible pathway for biologics that healthcare reform has provided, Merck currently has five biosimilars in late stage development.

Read the full story here.

Share this article with your social network, just click below to share now!

Share |